Biohaven

Biohaven Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Biohaven (BHVN) as of Oct 22, 2026 is 82.49 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 68.81 % — a change of 19.87% (higher).

Cash Conversion

82.49 %

YoY

19.87%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Biohaven is 2025 82.49 % . Cash Conversion Rate (OCF/Net Income) of Biohaven was 2024 68.81 % . It decreases by 19.87% higher compared to the previous year.

The Biohaven Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
81.83 USD
Jan 1, 2019
71.36 USD
Jan 1, 2020
64.01 USD
Jan 1, 2021
68.21 USD
Jan 1, 2022
52.20 USD
Jan 1, 2023
81.27 USD
Jan 1, 2024
68.81 USD
Jan 1, 2025
82.49 USD
The Biohaven Cash Conversion history
YEARCash ConversionYoY
82.49 %+19.87%
68.81 %-15.33%
81.27 %+55.69%
52.20 %-23.48%
68.21 %+6.57%
64.01 %-10.30%
71.36 %-12.80%
81.83 %+76.64%
46.33 %-17.22%
55.96 %-29.56%
79.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biohaven Stock analysis

What does Biohaven do? Biohaven Pharmaceutical Holding Co. Ltd. generates revenue through the research and development of late-stage product candidates targeting neurological diseases and rare disorders. The company utilizes its glutamate platform to advance clinical-stage compounds for various indications, including trigriluzole for obsessive-compulsive disorder, spinocerebellar ataxia, and Alzheimer's disease. Additionally, the firm develops BHV-0223 for amyotrophic lateral sclerosis and BHV-5000 for conditions such as Rett syndrome, neuropathic pain, and treatment-resistant depression. The business model focuses on identifying and developing clinical-stage compounds that target orphan neurologic indications and other neurological pathways, with the company currently employing 825 full-time employees in New Haven, Connecticut. Biohaven is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biohaven stock

Cash Conversion Rate (OCF/Net Income) of Biohaven is 82.49 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Biohaven changed from 68.81 % to 82.49 %, representing a 19.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Biohaven since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Biohaven with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biohaven

All Key Metrics — Biohaven